240 related articles for article (PubMed ID: 29382323)
1. Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions.
Paz-Zulueta M; Álvarez-Paredes L; Rodríguez Díaz JC; Parás-Bravo P; Andrada Becerra ME; Rodríguez Ingelmo JM; Ruiz García MM; Portilla J; Santibañez M
BMC Cancer; 2018 Jan; 18(1):112. PubMed ID: 29382323
[TBL] [Abstract][Full Text] [Related]
2. HPV genotypes co-infections associated with cervical carcinoma: Special focus on phylogenetically related and non-vaccine targeted genotypes.
Senapati R; Nayak B; Kar SK; Dwibedi B
PLoS One; 2017; 12(11):e0187844. PubMed ID: 29161285
[TBL] [Abstract][Full Text] [Related]
3. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
4. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions.
Li J; Gao JJ; Li N; Wang YW
Arch Virol; 2021 Mar; 166(3):853-862. PubMed ID: 33486629
[TBL] [Abstract][Full Text] [Related]
5. Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions.
Álvarez-Paredes L; Santibañez M; Galiana A; Rodríguez Díaz JC; Parás-Bravo P; Andrada-Becerra ME; Ruiz García MM; Rodríguez-Ingelmo JM; Portilla-Sogorb J; Paz-Zulueta M
Cancer Prev Res (Phila); 2019 Aug; 12(8):547-556. PubMed ID: 31208965
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
[TBL] [Abstract][Full Text] [Related]
8. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
9. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
11. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S; Gasparini R; Panatto D; Demarteau N
Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
[TBL] [Abstract][Full Text] [Related]
12. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
13. High rate of non-vaccine targeted high-risk HPV genotypes circulate among women in Eastern Ethiopia.
Seyoum A; Seyoum B; Gure T; Alemu A; Alemayehu DH; Alemu A; Belachew A; Tefera DA; Aseffa A; Howe R; Mulu A; Mihret A
Sci Rep; 2024 Jan; 14(1):958. PubMed ID: 38200092
[TBL] [Abstract][Full Text] [Related]
14. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results.
Guo M; Gong Y; Wang J; Dawlett M; Patel S; Liu P; Bevers TB; Sneige N
Cancer Cytopathol; 2013 Feb; 121(2):79-85. PubMed ID: 23225501
[TBL] [Abstract][Full Text] [Related]
15. Identification of vaccine human papillomavirus genotypes in squamous intraepithelial lesions (CIN2-3).
González-Bosquet E; Esteva C; Muñoz-Almagro C; Ferrer P; Pérez M; Lailla JM
Gynecol Oncol; 2008 Oct; 111(1):9-12. PubMed ID: 18684497
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
17. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Pearse A; Montoya GD; Robertson M; Shearman CA; Castle PE;
Int J Cancer; 2013 Jan; 132(1):198-207. PubMed ID: 22532127
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
[TBL] [Abstract][Full Text] [Related]
19. Potential coverage of circulating HPV types by current and developing vaccines in a group of women in Bosnia and Herzegovina with abnormal Pap smears.
Salimović-Bešić I; Hukić M
Epidemiol Infect; 2015 Sep; 143(12):2604-12. PubMed ID: 25578155
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
